Erlotinib.

Recent Results Cancer Res

Department of Oncology, Gastroenterology and Internal Medicine, Städtische Kliniken Esslingen, Hirschlandstr. 97, 73730, Esslingen, Germany.

Published: November 2018

The epidermal growth factor receptor (EGFR) has been implicated in a multiplicity of cancer-related signal transduction pathways like cellular proliferation, adhesion, migration, neoangiogenesis and apoptosis inhibition, all of which are important features of cancerogenesis and tumour progression. Its tyrosine kinase activity plays a central role in mediating these processes and has been intensely studied to exploit it as a therapeutic target. Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cell lung cancer and pancreatic cancer with emphasis to the approved small molecule erlotinib. Its clinical applications, evidence-based efficacy and toxicity as well as predictive markers of response are discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-91442-8_1DOI Listing

Publication Analysis

Top Keywords

tyrosine kinase
8
clinical applications
8
erlotinib epidermal
4
epidermal growth
4
growth factor
4
factor receptor
4
receptor egfr
4
egfr implicated
4
implicated multiplicity
4
multiplicity cancer-related
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!